biostudies-literatureKonar MNCRR NIH HHSNIAID NIH HHS627-36https://www.ebi.ac.uk/biostudies/studies/S-EPMC3719908biostudies-literatureUnknown208(4)<h4>Background</h4>Factor H (fH) binding protein (fHbp) is part of vaccines developed for prevention of meningococcal serogroup B disease. More than 610 fHbp amino acid sequence variants have been identified, which can be classified into 2 subfamilies. The extent of cross-protection within a subfamily has been difficult to assess because of strain variation in fHbp expression.<h4>Methods</h4>Using isogenic mutant strains, we compared cross-protective serum antibody responses of mice immunized with 7 divergent fHbp variants in subfamily B, including identification numbers (ID) 1 and 55, which were chosen for vaccine development.<h4>Results and conclusions</h4>In the presence of the human complement downregulator fH, the ability of the anti-fHbp antibodies to deposit sufficient complement C3The Journal of infectious diseasesImportance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.PMC3719908AI 99125R01 AI046464R01 AI 70955R01 AI099125C06 RR016226R01 AI082263AI 82263C06 RR 16226R01 AI070955AI 46464Konar MBeernink PTGranoff DMfalseImportance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.<h4>Background</h4>Factor H (fH) binding protein (fHbp) is part of vaccines developed for prevention of meningococcal serogroup B disease. More than 610 fHbp amino acid sequence variants have been identified, which can be classified into 2 subfamilies. The extent of cross-protection within a subfamily has been difficult to assess because of strain variation in fHbp expression.<h4>Methods</h4>Using isogenic mutant strains, we compared cross-protective serum antibody responses of mice immunized with 7 divergent fHbp variants in subfamily B, including identification numbers (ID) 1 and 55, which were chosen for vaccine development.<h4>Results and conclusions</h4>In the presence of the human complement downregulator fH, the ability of the anti-fHbp antibodies to deposit sufficient complement C32013-01-01T00:00:00Z2013 Aug2025-04-26T14:04:10.333Z2019-03-27T01:13:30ZS-EPMC37199082371565910.1093/infdis/jit239